PDUFA Fees Increased Again For Fiscal 2016
This article was originally published in The Tan Sheet
Application fees will rise less than 2%, bringing the submission cost for a full NDA or BLA with clinical data to $2.37 million. Establishment and product fees will increase less than 3% and 4%, respectively.
You may also be interested in...
Failed confirmatory trials for PD-1/L-1 inhibitor indications raise questions about marginal response rates in single-arm trials used to support accelerated approval, Oncology Center of Excellence leaders say in NEJM article that explains why the agency is taking six of these indications to its Oncologic Drugs Advisory Committee.
Benefits of independence from exogenous insulin outweighed the risks from long-term immunosuppression necessary with the allogeneic pancreatic islet cellular therapy, majority of panelists said, but they urged the FDA to limit the indication to a very small subpopulation of patients.
Agency wants to use pandemic-interrupted clinical trials to gauge how decentralized approaches impacted study integrity and to inform prospective use of such designs post-COVID.